Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.

Autor: Shah N; University of California San Francisco, San Francisco, CA, USA. Electronic address: Nina.Shah@ucsf.edu., Delforge M; University Hospital Leuven, Leuven, Belgium., San-Miguel J; Clínica Universidad de Navarra, CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain., Moshkovich O; ICON, Gaithersburg, MD, USA., Braverman J; Bristol Myers Squibb, Princeton, NJ, USA., Dhanda DS; Bristol Myers Squibb, Princeton, NJ, USA., Lanar S; ICON plc, Lyon, France., Miera M; ICON, Gaithersburg, MD, USA., Williams A; ICON plc, London, UK., Murphy R; ICON, Gaithersburg, MD, USA., Devlen J; ICON, Gaithersburg, MD, USA., Hege K; Bristol Myers Squibb, San Francisco, CA, USA., Campbell TB; Bristol Myers Squibb, Princeton, NJ, USA., Munshi NC; The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2022 Sep; Vol. 120, pp. 106921. Date of Electronic Publication: 2022 Jul 21.
DOI: 10.1016/j.leukres.2022.106921
Abstrakt: Objective: To understand the experience of patients with relapsed and refractory multiple myeloma (RRMM) receiving idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in the pivotal, phase 2 KarMMa trial.
Methods: Optional semi-structured interviews before leukapheresis (pre-treatment) captured expectations and after ide-cel infusion (1, 2, and 3 months post-treatment), assessed treatment experience, ide-cel advantages/disadvantages, and health and well-being. In a mixed-method analysis, treatment experiences were categorized by clinical response status, health and well-being, and self-reported recovery after infusion.
Results: Pre-treatment interviews indicated unmet treatment needs. In post-treatment interviews, most patients reported the positives of ide-cel outweighed negatives (69%, n = 27/39). Most common advantages of ide-cel were efficacy (18-64%), favorable side-effect profile (46-68%), and recovery time (13-18%); most common disadvantages were related to side effects (13-20%). When analyzed by clinical response, patients most often had stringent complete or very good partial response and improved health and well-being with mild or severe recovery from the infusion (27/58, 47%). Most patients with minimal clinical response reported mild infusion recovery (5/6, 83%).
Conclusions: Patient interviews before ide-cel treatment showed unmet needs in triple-class exposed RRMM. Post-treatment experiences generally favored ide-cel versus previously received treatments.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: